Viridian Therapeutics Inc (VRDN) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $29.49
• Market Cap: $2.76B
• EPS: $-3.03
• 52-Week High: $34.29
• 52-Week Low: $9.90

Market Sentiment

Viridian Therapeutics Inc currently has a Neutral sentiment score of 0.11.

About Viridian Therapeutics Inc

Viridian Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative therapies for patients suffering from rare and autoimmune disorders. Based in Boulder, Colorado, the company is focused on leveraging advanced research and development to deliver breakthrough treatments that meet significant unmet medical needs. With a strong pipeline of drug candidates and an unwavering commitment to enhancing patient outcomes, Viridian Therapeutics is poised to play a pivotal role ...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Viridian Therapeutics Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does VRDN pay dividends?

Viridian Therapeutics Inc (VRDN) does not currently pay a regular dividend.

What is VRDN's market cap?

Viridian Therapeutics Inc (VRDN) has a market capitalization of $2.76B with a current stock price of $29.49.